| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Whitfield Dianne C. | Chief Human Resources Officer | C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE | /s/ Jeffrey Farrow, Attorney-in-Fact | 06 Jan 2026 | 0001839516 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TARS | Common Stock | Sale | $457,714 | -5,715 | -15% | $80.09 | 33,243 | 02 Jan 2026 | Direct | F1, F2 |
| transaction | TARS | Common Stock | Sale | $655,527 | -8,122 | -24% | $80.71 | 25,121 | 02 Jan 2026 | Direct | F1, F3 |
| transaction | TARS | Common Stock | Sale | $68,386 | -835 | -3.3% | $81.90 | 24,286 | 02 Jan 2026 | Direct | F1, F4 |
| transaction | TARS | Common Stock | Sale | $74,056 | -893 | -3.7% | $82.93 | 23,393 | 02 Jan 2026 | Direct | F1, F5 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025. |
| F2 | The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $79.42 to $80.40. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $80.42 to $81.29. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F4 | The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $81.68 to $82.62. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F5 | The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $82.82 to $83.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |